Surmodics (NASDAQ:SRDX) Sees Unusually-High Trading Volume

Surmodics, Inc. (NASDAQ:SRDX) saw unusually-high trading volume on Monday . Approximately 406,885 shares traded hands during trading, an increase of 93% from the previous session’s volume of 211,054 shares.The stock last traded at $41.05 and had previously closed at $41.10.

Wall Street Analyst Weigh In

A number of research firms recently commented on SRDX. Lake Street Capital reissued a “hold” rating and issued a $43.00 price target on shares of Surmodics in a research report on Wednesday, May 29th. Barrington Research reiterated a “market perform” rating on shares of Surmodics in a report on Thursday, May 30th. Sidoti reissued a “neutral” rating and set a $43.00 price target on shares of Surmodics in a research report on Wednesday, May 29th. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a report on Monday, August 5th. Finally, StockNews.com began coverage on shares of Surmodics in a research note on Sunday. They issued a “hold” rating for the company. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $50.00.

Surmodics Trading Down 0.1 %

The stock has a market capitalization of $585.23 million, a PE ratio of 43.26 and a beta of 1.18. The company has a current ratio of 3.98, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25. The firm has a 50-day moving average price of $41.80 and a 200-day moving average price of $34.77.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SRDX. SG Americas Securities LLC bought a new stake in shares of Surmodics in the 4th quarter worth approximately $163,000. Hillsdale Investment Management Inc. increased its position in Surmodics by 15.7% in the fourth quarter. Hillsdale Investment Management Inc. now owns 4,570 shares of the company’s stock worth $166,000 after buying an additional 620 shares during the last quarter. Hardin Capital Partners LLC bought a new stake in shares of Surmodics in the second quarter valued at $206,000. Lazard Asset Management LLC raised its stake in shares of Surmodics by 13.4% in the first quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock valued at $166,000 after buying an additional 673 shares during the period. Finally, Bailard Inc. bought a new position in shares of Surmodics during the 2nd quarter worth $257,000. 96.63% of the stock is owned by institutional investors.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).